Current and Future PET Imaging for Multiple Myeloma

Current and Future PET Imaging for Multiple Myeloma

Positron emission tomography (PET) is an imaging modality used for the noninvasive assessment of tumor staging and response to therapy. PET with <sup>18</sup>F labeled fluorodeoxyglucose (<sup>18</sup>F-FDG PET) is widely used to assess the active and inactive lesions in pati...

Full description

Bibliographic Details
Main Authors:	Mariko Ishibashi, Miwako Takahashi, Taiga Yamaya, Yoichi Imai
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Life
Subjects:	multiple myeloma tumor microenvironment PET immuno-P radiotracer minimal residual disease
Online Access:	https://www.mdpi.com/2075-1729/13/8/1701

Similar Items

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview
by: Slavisa Ninkovic, et al.
Published: (2020-11-01)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
by: Clément Bailly, et al.
Published: (2020-06-01)

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI
by: Adele Santoni, et al.
Published: (2022-11-01)

Recent developments on the application of molecular probes in multiple myeloma: Beyond [18F]FDG
by: Shaojuan Zhang, et al.
Published: (2022-08-01)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
by: Sandy W. Wong, et al.
Published: (2021-12-01)

Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications
by: Theresia Akhlaghi, et al.
Published: (2022-07-01)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
by: Elena Zamagni, et al.
Published: (2020-10-01)

Minimal residual disease in multiple myeloma: current status
by: Hong Ding, et al.
Published: (2021-10-01)

Steps towards a Multiple Myeloma Cure?
by: Alessandro Gozzetti, et al.
Published: (2022-09-01)

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
by: Agnieszka Krzywdzińska, et al.
Published: (2021-10-01)

Future Directions in Maintenance Therapy in Multiple Myeloma
by: Sarah A. Holstein, et al.
Published: (2021-05-01)

The Role of 18F-FDG-PET/CT Scan in the Management of Multiple Myeloma
by: Shirin Haghighat
Published: (2020-07-01)

Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma
by: Nicolò Musso, et al.
Published: (2022-10-01)

Interest of Pet Imaging in Multiple Myeloma
by: Bastien Jamet, et al.
Published: (2019-04-01)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
by: Ioannis V. Kostopoulos, et al.
Published: (2020-05-01)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
by: Carlos Bravo-Pérez, et al.
Published: (2021-08-01)

Current Main Topics in Multiple Myeloma
by: Sonia Morè, et al.
Published: (2023-04-01)

Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
by: Aditi Mulgaonkar, et al.
Published: (2023-06-01)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
by: Noemí Puig, et al.
Published: (2021-09-01)

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
by: Jing Wang, et al.
Published: (2024-02-01)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
by: Konstantinos Papadimitriou, et al.
Published: (2020-11-01)

STUDY OF MINIMAL RESIDUAL DISEASE BY MULTICOLOR FLOW CYTOMETRY IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: I. V. Galtseva, et al.
Published: (2017-06-01)

FLOW CYTOMETRY IN THE DIAGNOSIS AND MONITORING OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
by: I. V. Galtseva, et al.
Published: (2017-06-01)

Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma
by: Volker Morath, et al.
Published: (2022-01-01)

Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
by: Giuseppe Bertuglia, et al.
Published: (2022-12-01)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
by: Roberto Mina, et al.
Published: (2020-07-01)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Elena Zamagni, et al.
Published: (2020-12-01)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
by: Alessandra Romano, et al.
Published: (2019-08-01)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
by: Charalampos Charalampous, et al.
Published: (2022-01-01)

Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group
by: Jelena Bila, et al.
Published: (2021-08-01)

Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins
by: Ping Bai, et al.
Published: (2020-08-01)

Multiple Myeloma: Case of a “Moving” Sternal Wire
by: Yun Song Choo, et al.
Published: (2023-06-01)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
by: Stefania Oliva, et al.
Published: (2020-01-01)

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
by: Valentina Marchica, et al.
Published: (2021-02-01)

High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
by: Yinlei Bai, et al.
Published: (2016-10-01)

Spinal cord involvement of multiple myeloma detected by F-18 FDG PET/CT Scan
by: İlknur Ak Sivrikoz, et al.
Published: (2010-12-01)

Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs
by: Iole Cordone, et al.
Published: (2023-03-01)

Whole-Body Functional MRI and PET/MRI in Multiple Myeloma
by: Sébastien Mulé, et al.
Published: (2020-10-01)

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
by: Anne-Victoire Michaud-Robert, et al.
Published: (2020-05-01)

C-11 Choline and FDG PET/CT Imaging of Primary Cholangiocarcinoma – a Comparative Analysis
by: Chanisa Chotipanich, et al.
Published: (2015-01-01)